Annual Review of Pharmacology and Toxicology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Gene-Environment Interactions: My Unique Journey
Annu Rev Pharmacol Toxicol. 2023 Oct 3. doi: 10.1146/annurev-pharmtox-022323-082311. Online ahead of print.ABSTRACTI am deeply honored to be invited to write this scientific autobiography. As a physician-scientist, pediatrician, molecular biologist, and geneticist, I have authored/coauthored more than 600 publications in the fields of clinical medicine, biochemistry, biophysics, pharmacology, drug metabolism, toxicology, molecular biology, cancer, standardized gene nomenclature, developmental toxicology and teratogenesis, mouse genetics, human genetics, and evolutionary genomics. Looking back, I think my career can be divi...
Source: Annual Review of Pharmacology and Toxicology - October 3, 2023 Category: Drugs & Pharmacology Authors: Daniel W Nebert Source Type: research

Anthracycline Toxicity: Light at the End of the Tunnel?
Annu Rev Pharmacol Toxicol. 2023 Oct 3. doi: 10.1146/annurev-pharmtox-022823-035521. Online ahead of print.ABSTRACTAnthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional valid...
Source: Annual Review of Pharmacology and Toxicology - October 3, 2023 Category: Drugs & Pharmacology Authors: Romina B Cejas Kateryna Petrykey Yadav Sapkota Paul W Burridge Source Type: research

Antiepileptic Drugs as Potential Dementia Prophylactics Following Traumatic Brain Injury
Annu Rev Pharmacol Toxicol. 2023 Oct 3. doi: 10.1146/annurev-pharmtox-051921-013930. Online ahead of print.ABSTRACTSeizures and other forms of neurovolatility are emerging as druggable prodromal mechanisms that link traumatic brain injury (TBI) to the progression of later dementias. TBI neurotrauma has both acute and long-term impacts on health, and TBI is a leading risk factor for dementias, including chronic traumatic encephalopathy and Alzheimer's disease. Treatment of TBI already considers acute management of posttraumatic seizures and epilepsy, and impressive efforts have optimized regimens of antiepileptic drugs (AED...
Source: Annual Review of Pharmacology and Toxicology - October 3, 2023 Category: Drugs & Pharmacology Authors: Laszlo F Locskai Hadeel Alyenbaawi W Ted Allison Source Type: research

Oral Anticoagulants Beyond Warfarin
Annu Rev Pharmacol Toxicol. 2023 Sep 27. doi: 10.1146/annurev-pharmtox-032823-122811. Online ahead of print.ABSTRACTDirect oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly warfarin, for the main indications for oral anticoagulation, prevention and treatment of venous thromboembolism, and prevention of embolic stroke in atrial fibrillation. While DOACs offer practical, fixed-dose anticoagulation in many patients, specific restrictions or contraindications may apply. DOACs are not sufficiently effective in high-thrombotic risk conditions such as antiphospholipid syndrome and mechanical heart va...
Source: Annual Review of Pharmacology and Toxicology - September 27, 2023 Category: Drugs & Pharmacology Authors: Renske H Olie Kristien Winckers Bianca Rocca Hugo Ten Cate Source Type: research

Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine
Annu Rev Pharmacol Toxicol. 2023 Sep 22. doi: 10.1146/annurev-pharmtox-022723-113921. Online ahead of print.ABSTRACTProteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of p...
Source: Annual Review of Pharmacology and Toxicology - September 22, 2023 Category: Drugs & Pharmacology Authors: Sunil K Joshi Paul Piehowski Tao Liu Sara J C Gosline Jason E McDermott Brian J Druker Elie Traer Jeffrey W Tyner Anupriya Agarwal Cristina E Tognon Karin D Rodland Source Type: research